Differentiation of lung adenocarcinoma, pleural mesothelioma, and nonmalignant pulmonary tissues using DNA methylation profiles

Cancer Research

Volumn 69, Issue 15, 2009, Pages 6315-6321

  Christensen, Brock C ^a,b   Marsit, Carmen J ^b   Houseman, E Andres ^a,c   Godleski, John J ^c   Longacker, Jennifer L ^d   Zheng, Shichun ^f   Yeh, Ru Fang ^f   Wrensch, Margaret R ^f   Wiemels, Joseph L ^f   Karagas, Margaret R ^g   Bueno, Raphael ^e   Sugarbaker, David J ^e   Nelson, Heather H ^h   Wiencke, John K ^f   Kelsey, Karl T ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

^c HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^d BOSTON UNIVERSITY SCHOOL OF PUBLIC HEALTH   (United States)

^e BRIGHAM AND WOMEN S HOSPITAL   (United States)

^f UNIVERSITY OF CALIFORNIA   (United States)

^g DARTMOUTH MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DNA; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER CLASSIFICATION; CELL CYCLE REGULATION; CONTROLLED STUDY; CPG ISLAND; DIAGNOSTIC ACCURACY; DIFFERENTIAL DIAGNOSIS; DNA DAMAGE; DNA METHYLATION; FEMALE; GENE LOCUS; HUMAN; HUMAN TISSUE; LUNG ADENOCARCINOMA; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; PLEURA MESOTHELIOMA; PRIORITY JOURNAL; PROMOTER REGION; RANDOM FOREST; SIGNAL TRANSDUCTION;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; CPG ISLANDS; CYTOSINE; DIAGNOSIS, DIFFERENTIAL; DNA METHYLATION; FEMALE; HUMANS; LUNG DISEASES; LUNG NEOPLASMS; MALE; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS;

EID: 68049147571     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-09-1073     Document Type: Article

References (33)

1. Holloway AJ, Diyagama DS, Opeskin K, et al. A molecular diagnostic test for distinguishing lung adenocarcinoma from malignant mesothelioma using cells collected from pleural effusions. Clin Cancer Res 2006;12:5129-5135 (Pubitemid 44453340)
2. Robinson BW, Lake RA. Advances in malignant mesothelioma. The New England Journal of Medicine 2005;353:1591-1603
3. Nguyen GK, Akin MR, Villanueva RR, Slatnik J. Cytopathology of malignant mesothelioma of the pleura in fine-needle aspiration biopsy. Diagn Cytopathol 1999;21:253-259 (Pubitemid 29459879)
4. Antman KH. Current concepts: malignant mesothelioma. N Engl J Med 1980;303:200-202
5. Chang MY, Sugarbaker DJ. Extrapleural pneumonectomy for diffuse malignant pleural mesothelioma: techniques and complications. Thorac Surg Clin 2004;14:523-530 (Pubitemid 39314486)
6. Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc 2008;83:584-594 (Pubitemid 351720831)
7. Renshaw AA, Dean BR, Antman KH, Sugarbaker DJ, Cibas ES. The role of cytologic evaluation of pleural fluid in the diagnosis of malignant mesothelioma. Chest 1997;111:106-109 (Pubitemid 27043616)
8. Ylagan LR, Zhai J. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Diagnostic Cytopathology 2005;32:137-144 (Pubitemid 40256262)
9. Marchevsky AM. Application of immunohistochemistry to the diagnosis of malignant mesothelioma. Archiv Pathol Laboratory Med 2008;132:397-401. (Pubitemid 351328814)
10. Marchevsky AM, Wick MR. Evidence-based guidelines for the utilization of immunostains in diagnostic pathology: pulmonary adenocarcinoma versus mesothelioma. Appl Immunohistochem Mol Morphol 2007;15:140-144
11. Gordon GJ, Jensen RV, Hsiao LL, et al. Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. Cancer Res 2002;62:4963-4967
12. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev 2002;16:6-21. (Pubitemid 34049633)
13. Jones PA, Baylin SB. The fundamental role of epigenetic events in cancer. Nat Rev 2002;3:415-428
14. Bibikova M, Lin Z, Zhou L, et al. High-throughput DNA methylation profiling using universal bead arrays. Genome Res 2006;16:383-393 (Pubitemid 43327509)
15. Christensen BC, Houseman EA, Godleski JJ, et al. Epigenetic profiles distinguish pleural mesothelioma from normal pleura and predict lung asbestos burden and clinical outcome. Cancer Res 2009;69:227-234
16. Toyooka S, Pass HI, Shivapurkar N, et al. Aberrant methylation and simian virus 40 tag sequences in malignant mesothelioma. Cancer Res 2001;61:5727-5730 (Pubitemid 32769086)
17. Tsou JA, Shen LY, Siegmund KD, et al. Distinct DNA methylation profiles in malignant mesothelioma, lung adenocarcinoma, and non-tumor lung. Lung Cancer 2005;47:193-204.
18. Wiencke JK, Kelsey KT, Varkonyi A, et al. Correlation of DNA adducts in blood mononuclear cells with tobacco carcinogen-induced damage in human lung. Cancer Res 1995;55:4910-4914
19. R Development CT. R: A Language and Environment for Statistical Computing. Vienna (Austria): R Foundation for Statistical Computing; 2007.
20. Houseman EA, Christensen BC, Marsit CJ, et al. Model-based clustering of DNA methylation array data: a recursive-partitioning algorithm for high-dimensional data arising as a mixture of h distributions. BMC Bioinformatics 2008;9:365.
21. Hsiung DT, Marsit CJ, Houseman EA, et al. Global DNA methylation level in whole blood as a biomarker in head and neck squamous cell carcinoma. Cancer Epidemiol Biomarkers Prev 2007;16:108-114
22. Storey J, Taylor J, Siegmund D. Strong control, conservative point estimation, and simultaneous conservative consistency of false discovery rates: A unified approach. J Royal Stat Soc 2004;Series B:187-205. (Pubitemid 38210666)
23. Brieman L. Random Forests. Machine Learning 2001;45:5-32.
24. Ingenuity Pathways Analysis application. 6.3, build 54960 ed: Ingenuity Systems; 2008.
25. Shiota K. DNA methylation profiles of CpG islands for cellular differentiation and development in mammals. Cytogenet Genome Res 2004;105:325-334 (Pubitemid 38979696)
26. Rakyan VK, Hildmann T, Novik KL, et al. DNA methylation profiling of the human major histocompatibility complex: a pilot study for the human epigenome project. PLoS Biol 2004;2:e405. (Pubitemid 40284135)
27. Schilling E, Rehli M. Global, comparative analysis of tissue-specific promoter CpG methylation. Genomics 2007;90:314-323 (Pubitemid 47176332)
28. Christensen BC, Godleski JJ, Marsit CJ, et al. Asbestos exposure predicts cell cycle control gene promoter methylation in pleural mesothelioma. Carcinogenesis 2008;29:1555-1559
29. Marsit CJ, Kim DH, Liu M, et al. Hypermethylation of RASSF1A and BLU tumor suppressor genes in non-small cell lung cancer: implications for tobacco smoking during adolescence. Int J Cancer 2005;114:219-223 (Pubitemid 40194289)
30. Kim DH, Nelson HH, Wiencke JK, et al. p16(INK4a) and histology-specific methylation of CpG islands by exposure to tobacco smoke in non-small cell lung cancer. Cancer Res 2001;61:3419-3424
31. Toyooka S, Maruyama R, Toyooka KO, et al. Smoke exposure, histologic type and geography-related differences in the methylation profiles of non-small cell lung cancer. Int J Cancer 2003;103:153-160 (Pubitemid 35461506)
32. Cheng JQ, Jhanwar SC, Klein WM, et al. p16 alterations and deletion mapping of 9p21-22 in malignant mesothelioma. Cancer Res 1994;54:5547-5551 (Pubitemid 2158337)
33. Hirao T, Bueno R, Chen CJ, Gordon GJ, Heilig E, Kelsey KT. Alterations of the p16(INK4) locus in human malignant mesothelial tumors. Carcinogenesis 2002;23:1127-1130 (Pubitemid 34814769)